scholarly journals Tumor Lysis Syndrome in Solid Tumors: A Comprehensive Literature Review, New Insights, and Novel Strategies to Improve Outcomes

Cureus ◽  
2020 ◽  
Author(s):  
Dawood Findakly ◽  
Ross D Luther ◽  
Jue Wang
2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Danica Maria Vodopivec ◽  
Jose Enrique Rubio ◽  
Alessia Fornoni ◽  
Oliver Lenz

Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia in patients with a malignancy. When these laboratory abnormalities develop rapidly, clinical complications such as cardiac arrhythmias, acute renal failure, seizures, or death may occur. TLS is caused by rapid release of intracellular contents by dying tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be reported in the literature. We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day. Our methodology involved identifying key articles from existing reviews of the literature and then using search terms from these citations in MEDLINE to find additional publications. We relied on a literature review published in 2003 by Baeksgaard et al., where they gathered all total 45 cases reported from 1977 to 2003. Then, we looked for new reported cases from 2004 to present day. All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.


2009 ◽  
Vol 27 (16) ◽  
pp. 2738-2739 ◽  
Author(s):  
Cengiz Gemici

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Vivek Alaigh ◽  
Debapriya Datta

Tumor lysis syndrome (TLS) is an oncologic emergency characterized by a combination of metabolic derangements (hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia) caused by rapid turnover from cell destruction in certain cancers. These metabolic derangements can lead to seizures, cardiac arrhythmias, renal failure, and death. TLS is usually seen after the initiation of chemotherapy for hematologic malignancies. TLS occurring spontaneously, without initiation of chemotherapy, is rare and its occurrence in solid tumors is rarer still. We report a case of spontaneous TLS in a patient with leiomyosarcoma of the uterus, with metastasis to lung. Such a case has never been reported before.


2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18766-e18766
Author(s):  
Jonathan Harmon ◽  
Sarah Allen ◽  
Jill Cassaday ◽  
Kirill Ruvinov ◽  
Desi Stoyanova ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Neeraj Saini ◽  
Kyeong Pyo Lee ◽  
Smita Jha ◽  
Sanket Patel ◽  
Neelima Bonthu ◽  
...  

Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis. It is commonly associated with hematological cancers like leukemia and lymphoma and uncommonly with solid nonhematologic tumors as well. However, spontaneous tumor lysis syndrome (STLS) without any cytotoxic chemotherapy rarely occurs in solid tumors. We describe a case of STLS in a metastatic adenocarcinoma of unknown primary and review the literature of STLS in solid non-hematologic tumors to identify various risk factors for pathogenesis of this entity.


2005 ◽  
Vol 2 (3) ◽  
pp. 188-191 ◽  
Author(s):  
Frank E. Mott ◽  
Alex Esana ◽  
Carl Chakmakjian ◽  
Jon D. Herrington

Rare Tumors ◽  
2014 ◽  
Vol 6 (2) ◽  
pp. 68-76 ◽  
Author(s):  
Aibek E. Mirrakhimov ◽  
Alaa M. Ali ◽  
Maliha Khan ◽  
Aram Barbaryan

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19098-e19098
Author(s):  
Dhiran Verghese ◽  
Phyo Thazin Myint ◽  
Faisal S. Ali ◽  
Nivedita Sundararajan ◽  
Zimu Gong ◽  
...  

e19098 Background: Tumor lysis syndrome (TLS) is a life-threatening oncological emergency. Spontaneous TLS (STLS) in solid tumors occurring prior to initiation of therapy is a rarely reported entity and has poor outcomes. Little is known about the prognostic factors influencing STLS in solid tumors. Methods: A systematic search of Medline, PubMed, and Embase was conducted to identify reports of patients ≥18 years diagnosed with STLS in solid tumors. Individual case reports and case series were summarized, and descriptive statistics were employed to report clinical outcomes. Fischer exact t test was used for statistical analysis. Results: 63 patients from 61 case reports and one patient from our institution resulted in a total of 64 patients. 53.1% were males with a median age of 56.1 years. The most common solid tumors were of pulmonary origin. 85.9% patients had stage 4 malignancy, 75.0% had hepatic involvement. The most common presenting symptom was abdominal discomfort. The mean serum potassium, phosphorus, uric acid, calcium, lactate dehydrogenase, and creatinine upon presentation were 6.1 mmol/l, 7.5 mg/dl, 16.4 mg/dl, 7.5 mg/dl, 4421.2 IU/L and 3.7 mg/dl, respectively. In addition to intravenous hydration, allopurinol and rasburicase were administered in 48.4% and 42.2% patients. Urinary alkalization and sodium bicarbonate administration were reported in 6.3% and 15.6% patients. 43.8% patients required hemodialysis and 39 patients died (mortality of 60.9%). Patients who underwent hemodialysis had a similar mortality of 60.4%. We assessed liver involvement (primary hepatocellular carcinoma and hepatic metastasis) as a potential prognostic factor. Compared to patients without liver involvement, patients with liver involvement had a higher unadjusted all-cause mortality (70.83% vs 25%; OR 7.29 [95% CI 1.71 - 30.98]; p = 0.006). Conclusions: Hepatic involvement is a potential prognostic factor for STLS in solid tumors and is associated with a grave prognosis. Future large prospective studies are needed to probe into the role of early hemodialysis and to identify other prognostic factors of STLS in solid tumors.


2016 ◽  
Vol 26 ◽  
Author(s):  
Clarissa Veloso Souto Gandra ◽  
Maria Thereza Mansur Starling ◽  
Natália Nicolai Gomes ◽  
Raquel Soares Carvalho ◽  
Silvia Veloso Souto Gandra

Sign in / Sign up

Export Citation Format

Share Document